(Reuters) - Amgen Inc and Kite Pharma Inc said they entered into a deal to develop and market cancer immunotherapies using Amgen's cancer targets and Kite's technology platform. Amgen will pay Kite Pharma $60 million upfront and fund research costs through the filing of a new drug application. After that each company will conduct and fund trials for their therapeutic candidates, they said in a joint statement. ...
via Health News Headlines - Yahoo News http://ift.tt/13T2OES
via Health News Headlines - Yahoo News http://ift.tt/13T2OES
No comments:
Post a Comment